SecBot SecBot
PRESS-RELEASE ·Filed Jul 20, 2026

TLX

Telix Pharmaceuticals Limited
BULLISH
Impact 4/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Phase 3 initiation adds incremental pipeline value but is not a near-term catalyst. Monitor for enrollment updates and eventual data readouts. The stock has historically not reacted strongly to this type of announcement, so the near-term trading impact is likely muted.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK AT ENTRY AT T+60
Entry
$10.92
T+0 close · Jul 20, 2026 · via day close
Latest settled
0.00%
T+60 · $10.92
Vs SPY
−3.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 21 $10.92entry
  2. T+1 · 4mo ago −5.49%α −5.38% · $10.32
  3. T+5 · 4mo ago −8.61%α −7.38% · $9.98
  4. T+20 · 3mo ago +8.79%α +6.23% · $11.88
  5. T+60 · 5w ago 0.00%α −3.97% · $10.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix Pharmaceuticals announced the first patient dosed in its Phase 3 LUTEON1 trial evaluating TLX250-Tx, a CAIX-targeted radiopharmaceutical therapy, in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). This is a positive clinical milestone, but the event is procedural without financial data or near-term catalysts, and the company's stock has historically not reacted strongly to similar announcements.

Key Facts

  • First patient dosed in the Phase 3 LUTEON1 trial of TLX250-Tx for relapsed or recurrent ccRCC.
  • LUTEON1 is the first Phase 3 study of a CAIX-targeted radiopharmaceutical therapy in ccRCC.
  • Telix has a commercial imaging franchise (Illuccix, Gozellix) and multiple late-stage therapeutic candidates, including TLX250-Tx.

Financial Impact

No financial impact disclosed; clinical milestone only.

Risk Factors

  • Clinical trial failure risk (efficacy, safety, or enrollment delays).
  • Regulatory approval risk for TLX250-Tx, which has not received marketing authorization in any jurisdiction.
  • Competition from existing and emerging therapies for clear cell renal cell carcinoma.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3330128

Track record

27 reports on TLX

Performance horizon

10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (9h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026